Announced
Synopsis
Teijin, a technology-driven global group, agreed to acquire Ascendis Pharma, a biopharma company, for $70m. “Ascendis has leveraged its innovative TransCon technology platform to create a suite of highly differentiated product candidates with best-in-class potential that complement our existing pharmaceutical portfolio,” Akimoto Uchikawa, Teijin Limited President and Chief Executive Officer.
Principals
Show Details & Financials
Did you work on this deal?
Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.